文献速递帕金森病与运动障碍认知障碍与痴呆

早期帕金森病患者与健康对照的纵向脑脊液生物标志物分析

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
PubMed 文献 · Neurology · 2017-10-13

该研究在帕金森进展标志物计划中,对173例早期未用药帕金森病患者和112例匹配健康对照,在基线、6个月和12个月检测脑脊液α-突触核蛋白、总tau、磷酸化tau和β-淀粉样蛋白1-42。核心生物标志物在12个月内保持稳定,仅Aβ42小幅显著升高,p-tau/t-tau比值升高而t-tau/Aβ42下降,但变化与运动评分或 dopamine 成像无关。使用多巴胺替代治疗(尤其多巴胺激动剂)的患者12个月时脑脊液α-突触核蛋白水平更低。

要点

  • 早期帕金森病患者脑脊液核心生物标志物在12个月内总体稳定。
  • 仅Aβ42小幅升高,p-tau/t-tau升高而t-tau/Aβ42下降。
  • 生物标志物变化与运动症状进展或dopamine成像无相关性。

核心结论

  • 早期帕金森病患者和健康对照的脑脊液核心生物标志物在6和12个月内保持稳定。
  • 帕金森病药物使用可能影响脑脊液α-突触核蛋白水平。
  • 需要新型生物标志物来更好地刻画帕金森病的进展性神经退行性变。

研究设计与样本

  • 国际多中心帕金森进展标志物计划(PPMI)的纵向观察研究。
  • 纳入173例未用药帕金森病患者和112例匹配健康对照。
  • 在基线、6个月和12个月检测脑脊液α-突触核蛋白、总tau、磷酸化tau和β-淀粉样蛋白1-42。

主要发现

  • 脑脊液生物标志物在6和12个月内稳定,帕金森病患者和健康对照的Aβ42从基线至12个月均小幅显著升高。
  • 总tau保持稳定,帕金森病患者磷酸化tau升高略多于健康对照。
  • 帕金森病患者12个月内p-tau/t-tau比值升高,t-tau/Aβ42下降。
  • 脑脊液生物标志物变化与MDS-UPDRS运动评分变化或多巴胺成像变化无相关性。
  • 接受多巴胺替代治疗(尤其多巴胺激动剂)的帕金森病患者12个月时脑脊液α-突触核蛋白水平更低。

临床怎么用

  • 早期帕金森病患者脑脊液核心生物标志物在12个月内相对稳定,不宜单独用于短期监测疾病进展。
  • 解读脑脊液α-突触核蛋白时需考虑多巴胺替代治疗(尤其多巴胺激动剂)的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze longitudinal levels of CSF biomarkers in drug-naive patients with Parkinson disease (PD) and healthy controls (HC), examine the extent to which these biomarker changes relate to clinical measures of PD, and identify what may influence them. METHODS: CSF α-synuclein (α-syn), total and phosphorylated tau (t- and p-tau), and β-amyloid 1-42 (Aβ42) were measured at baseline and 6 and 12 months in 173 patients with PD and 112 matched HC in the international multicenter Parkinson's Progression Marker Initiative. Baseline clinical and demographic variables, PD medications, neuroimaging, and genetic variables were evaluated as potential predictors of CSF biomarker changes. RESULTS: CSF biomarkers were stable over 6 and 12 months, and there was a small but significant increase in CSF Aβ42 in both patients with patients with PD and HC from baseline to 12 months. The t-tau remained stable. The p-tau increased marginally more in patients with PD than in HC. α-syn remained relatively stable in patients with PD and HC. Ratios of p-tau/t-tau increased, while t-tau/Aβ42 decreased over 12 months in patients with PD. CSF biomarker changes did not correlate with changes in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale motor scores or dopamine imaging. CSF α-syn levels at 12 months were lower in patients with PD treated with dopamine replacement therapy, especially dopamine agonists. CONCLUSIONS: These core CSF biomarkers remained stable over 6 and 12 months in patients with early PD and HC. PD medication use may influence CSF α-syn. Novel biomarkers are needed to better profile progressive neurodegeneration in PD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Mollenhauer B, Caspell-Garcia CJ, Coffey CS, et al. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology. 2017. PMID: 29030452. doi:10.1212/WNL.0000000000004609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。